The Latest Breaking News from Jemperli

Jemperli Wins Accelerated FDA Approval for a Rectal Cancer Subtype as Most Trial Patients Avoided Surgery

FDA gave Jemperli accelerated approval for dMMR rectal cancer. Most trial patients skipped surgery, but the data are interim. What patients should ask.

Medical Daily · 6h ago

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK plc (NYSE:GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ:ANAB) in the Delaware Chancery Court.

Benzinga · Nov 21, 2025

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

AnaptysBio, Inc. (NASDAQ:ANAB) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.

Benzinga · Sep 30, 2025